FOLH1 and Familial prostate cancer: Less bulky than monoclonal antibodies, bombesin analog peptides are also interesting vectors for prostate cancer radionuclide therapy as they target a different protein from PSMA, namely the gastrin-releasing peptide receptor (GRPR).